Annovis Bio Receives DSMB Approval to Continue Pivotal Phase 3 Alzheimer's Trial
ANVS has more than doubled off its 52-week low of $1.11 on light trading volume (0.2× avg).
Summary
Annovis Bio announced that its independent Data and Safety Monitoring Board (DSMB) approved the continuation of its pivotal Phase 3 Alzheimer's disease clinical trial for buntanetap, citing no safety concerns at 6 months.
Key Events · Product Development and Regulatory · ANVS
-
DSMB Approves Phase 3 AD Trial Continuation
The independent Data and Safety Monitoring Board (DSMB) issued a positive recommendation, supporting the continuation of the pivotal Phase 3 Alzheimer's disease (AD) clinical trial for buntanetap without modification.
-
Positive 6-Month Safety Data
The DSMB concluded that no safety concerns were identified after a comprehensive evaluation of 6-month safety data in Alzheimer's patients, consistent with observations in Parkinson's patients.
-
Potential for Combined Safety Data Submission
The FDA indicated it may consider accepting combined safety data from both the Alzheimer's and Parkinson's studies in a future New Drug Application (NDA) submission.
-
Trial Enrollment 40% Complete
The pivotal Phase 3 AD clinical trial is currently recruiting patients across the United States and is 40% complete, with efficacy readouts anticipated in early 2027 and early 2028.
Analysis · ANVS · Life Sciences
Annovis Bio's receipt of a positive recommendation from the independent Data and Safety Monitoring Board (DSMB) for its pivotal Phase 3 Alzheimer's disease trial is a significant de-risking event. The DSMB's conclusion of no safety concerns at 6 months reinforces confidence in buntanetap's safety profile, allowing the trial to proceed without modification. The FDA's indication that it may consider accepting combined safety data from both Alzheimer's and Parkinson's studies could streamline future regulatory submissions, representing a positive signal for the company's development pathway. This update follows recent positive pipeline updates and confirms the trial's continued progress.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $2.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $62.8M. The 52-week trading range was $1.11 to $5.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.